Jaime Velie
Family · Neenah, WINPI 1295284560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,785 of the $9,387 with a category attached, or 72.3%. 27 manufacturers reported payments, led by AbbVie at 33.5% of the total. Reporting peaked in 2021 at $5,792 and has fallen 92.2% since, to $451 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $90.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biohaven Pharmaceuticals, Inc.$3K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Pfizer$178
- Biogen$170
- UCB, Inc.$115
- plus $786 from 21 others
What the payments were for
- Speaking & faculty fees$6,78572%
- Travel & lodging$5266%
- Food & beverage$2,07622%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $3,143 |
| Biohaven Pharmaceuticals, Inc. | 10 | $2,887 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $2,109 |
| Pfizer | 10 | $178 |
| Biogen | 4 | $170 |
| UCB, Inc. | 4 | $115 |
| Lundbeck LLC | 5 | $87 |
| Axsome Therapeutics, Inc. | 1 | $80 |
| Kyowa Kirin, Inc. | 3 | $69 |
| SK Life Science, Inc. | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Genentech USA, Inc. | 3 | $56 |
| Neurelis, Inc. | 2 | $49 |
| TG Therapeutics, Inc. | 2 | $44 |
| GE HealthCare | 1 | $28 |
| Argenx US, Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $25 |
| Eisai Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| EMD Serono, Inc. | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $18 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$4,826
- UBRELVY$2,570
How this compares
$9,387 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 78 | $107,824 |
| Emgality PenGalcanezumab-Gnlm | 78 | $56,449 |
| QuliptaAtogepant | 42 | $44,277 |
| UbrelvyUbrogepant | 31 | $29,914 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $29,755 |
| ReyvowLasmiditan Succinate | 28 | $20,850 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $8,479 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,311 |
| Lacosamide | 39 | $7,224 |
| Dihydroergotamine Mesylate | 12 | $5,797 |
| Gabapentin ErGabapentin | 19 | $3,483 |
| Gabapentin | 154 | $2,140 |
| Clobazam | 12 | $2,129 |
| Pregabalin | 84 | $1,751 |
| Propranolol Hcl ErPropranolol Hcl | 30 | $1,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $178 | $107,82478 claims |
| AbbVieQulipta, Ubrelvy | $3,143 | $74,19173 claims |
| Lilly USA, LLCReyvow | $20 | $20,85028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Neenah
- Heather BeckNeenah$4K
- Stephanie OffordMilwaukee$116K
- Laura SwobodaMenomonee Falls$111K
- Lonniel BainMadison$54K
- Linda WespGlendale$44K
- Andrea BuxtonGreen Bay$36K
- Jani CookGreen Bay$31K
- Tiffany HolleySheboygan$26K
- Kathryn SweetmanMenomonee Falls$26K
- Tracy NelsonMilwaukee$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.